TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

25 авг 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

22 авг 2022 06:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 авг 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2022 Financial Results

04 авг 2022 06:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Updates on its Development Programs

03 авг 2022 15:05:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2022 Financial Results

28 июл 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 июл 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 июн 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

02 июн 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

17 май 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

16 май 2022 06:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 май 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2022 Financial Results

05 май 2022 15:01:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

03 май 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2022 Financial Results

28 апр 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

20 апр 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 апр 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022

06 апр 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

21 мар 2022 06:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 мар 2022 16:00:00 Источник Nasdaq GlobeNewswire